MEDIVIR AB – INTERIM REPORT JANUARY – MARCH 2018

Successful financing enables project portfolio advancementSignificant events during the quarter · The holders of series A shares have notified the Company that they will convert all their series A shares to series B shares. · Successful completion of pre-clinical safety studies with MIV-818, enabling start of phase I clinical studies in 2018. · Preclinical data on MIV-818 were presented at the 2018 HCC Summit organized by the European Association for the Study of the Liver. The data demonstrating targeting of the active metabolite to the liver and identifying potential biomarkers